Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in giant cell arteritis
NL-OMON45913Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Sarilumab plus corticosteroid taper with Placebo plus corticosteroid taper (2 arms). Primary endpoint: Proportion of patients achieving sustained remission. Started Jul 2019; status: active, not recruiting.
02
Drugs
sarilumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NL-OMON45913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45913.